Compare ECOR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECOR | IFRX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 66.0M |
| IPO Year | 2018 | 2017 |
| Metric | ECOR | IFRX |
|---|---|---|
| Price | $10.20 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $6.25 |
| AVG Volume (30 Days) | 171.3K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,032,000.00 | N/A |
| Revenue This Year | $33.60 | N/A |
| Revenue Next Year | $30.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.20 | N/A |
| 52 Week Low | $4.16 | $0.74 |
| 52 Week High | $10.40 | $2.95 |
| Indicator | ECOR | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.94 | 34.76 |
| Support Level | $4.92 | $1.15 |
| Resistance Level | $10.37 | $1.82 |
| Average True Range (ATR) | 1.16 | 0.17 |
| MACD | 0.08 | -0.11 |
| Stochastic Oscillator | 93.88 | 5.78 |
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.